Immunogenicity and safety of COVID-19 vaccine BNT162b2 for patients with solid cancer: a large cohort prospective study from a single institution

CONCLUSIONS: BNT162b2 assures serological immunization without clinically significant toxicity in CP.The second dose is needed to reach a satisfactory humoral response.PMID:34583970 | DOI:10.1158/1078-0432.CCR-21-2439

Source: Clinical Genitourinary Cancer - September 29, 2021 Category: Cancer & Oncology Authors: Vincenzo Di Noia Fulvia Pimpinelli Davide Renna Vittoria Barberi Maria Teresa Maccallini Ludovica Gariazzo Martina Pontone Alessandro Monti Flaminia Campo Emanuela Taraborelli Maria Di Santo Fabrizio Petrone Chiara Mandoj Virginia Ferraresi Gianluigi Ferr Source Type: research